<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03768713</url>
  </required_header>
  <id_info>
    <org_study_id>JC101320-FC</org_study_id>
    <nct_id>NCT03768713</nct_id>
  </id_info>
  <brief_title>Impact of Suvorexant on Sympathetic Nerve Activity and Baroreflex Function in Chronic Insomnia</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Study to Determine the Effect of Suvorexant (Belsomra®) on Sympathetic Neural Activity and Baroreflex Function in Patients With Chronic Insomnia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montana State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Montana State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the effect of Suvorexant on sympathetic nerve activity and&#xD;
      baroreflex function in subject with chronic insomnia. The investigator's central hypothesis&#xD;
      is that Suvorexant will reduce sympathetic nerve activity and improve baroreflex function&#xD;
      when compared to placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will utilize a randomized, double-blind, placebo-controlled experimental approach&#xD;
      to determine the effects of 8-wk treatment with Suvorexant (Belsomra®) on sympathetic nerve&#xD;
      activity and baroreflex function in male and female subjects with chronic insomnia. The study&#xD;
      will utilize established techniques for assessing sleep (polysomnography), blood pressure&#xD;
      (sphygmomanometer and beat-to-beat finger plethysmography), and peripheral sympathetic nerve&#xD;
      activity (microneurography). The study will stratify enrollment based upon both age and sex&#xD;
      (i.e., male vs. female) because these two covariates are known to influence sympathetic nerve&#xD;
      activity and baroreflex function.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 18, 2019</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sympathetic nerve activity</measure>
    <time_frame>8 weeks</time_frame>
    <description>Direct recordings of muscle sympathetic nerve activity from the peroneal nerve using a microelectrode.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Baroreflex sensitivity</measure>
    <time_frame>8 weeks</time_frame>
    <description>The linear relationship between changes in beat-to-beat diastolic arterial pressure and changes in sympathetic nerve activity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sympathetic reactivity</measure>
    <time_frame>8 weeks</time_frame>
    <description>The change in muscle sympathetic nerve activity during a cold pressor test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Home sleep quality: Wrist actigraphy</measure>
    <time_frame>8 weeks</time_frame>
    <description>Wrist actigraphy will be used to to determine the quality of sleep, with a primary focus on sleep efficiency.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory sleep quality: Polysomnography</measure>
    <time_frame>8 week</time_frame>
    <description>Polysomnography will be used to determine the quality of sleep, with a primary focus on sleep efficiency.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Chronic Insomnia</condition>
  <arm_group>
    <arm_group_label>Drug (Suvorexant)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mg of Suvorexant daily (taken orally ~1 hour before bedtime)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>20 mg of Placebo daily (taken orally ~1 hour before bedtime)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Suvorexant</intervention_name>
    <description>Insomnia subjects will take a nightly pill of 20 mg Suvorexant for eight weeks.</description>
    <arm_group_label>Drug (Suvorexant)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Insomnia subjects will take a nightly pill of 20 mg placebo for eight weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Minimum 3 months of clinically diagnosed insomnia&#xD;
&#xD;
          -  Body mass index ≤35 kg/m2&#xD;
&#xD;
          -  Insomnia Severity Index (ISI) &gt; 7 arbitrary units (i.e., mild-to-severe insomnia)&#xD;
&#xD;
          -  Pre-menopausal women must have regular menstrual cycles (~26-30 day cycles) and will&#xD;
             be scheduled for microneurography 2-7 days after menstruation to consistently test&#xD;
             during the early follicular phase (or low-hormone phase in women on contraceptives)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current or prior treatment of Suvorexant.&#xD;
&#xD;
          -  Obstructive sleep apnea defined as an apnea-hypopnea index &gt; 30 using an FDA approved&#xD;
             home sleep apnea screening devices as used in routine clinical practice.&#xD;
&#xD;
          -  Participants without evidence of clinically significant obstructive sleep apnea on the&#xD;
             screening test will undergo an overnight in-laboratory polysomnography to confirm&#xD;
             absence of sleep apnea (apnea-hypopnea index of ≥ 30 episodes per hour) and to exclude&#xD;
             other sleep disorders (e.g. periodic limb movement arousal index of ≥ 5 episodes per&#xD;
             hour)&#xD;
&#xD;
          -  Circadian rhythm sleep disorders&#xD;
&#xD;
          -  History of meeting DSM-V criteria of major psychiatric disorder&#xD;
&#xD;
          -  Have been clinically-diagnosed with diabetes, cardiovascular disease, or any other&#xD;
             unstable or serious medical condition.&#xD;
&#xD;
          -  Current, or use within past month, of psychoactive (other than stable treatment with&#xD;
             antidepressant or antianxiety), hypnotic, stimulant or analgesic medication (except&#xD;
             occasional non-narcotic analgesics)&#xD;
&#xD;
          -  Shift work or other types of self-imposed irregular sleep schedules&#xD;
&#xD;
          -  Habitual smoking (6 or more cigarettes per week)&#xD;
&#xD;
          -  Habitual alcohol consumption (more than 2 alcoholic drinks per day)&#xD;
&#xD;
          -  Breastfeeding or pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason Carter, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montana State University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne Tikkanen</last_name>
    <phone>406-994-2292</phone>
    <email>anne.tikkanen@montana.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jeremy Bigalke</last_name>
    <phone>406-994-2292</phone>
    <email>jeremy.bigalke@student.montana.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Montana State University</name>
      <address>
        <city>Bozeman</city>
        <state>Montana</state>
        <zip>59717</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Tikkanen</last_name>
      <phone>406-994-2292</phone>
      <email>anne.tikkanen@montana.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 5, 2018</study_first_submitted>
  <study_first_submitted_qc>December 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2018</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Suvorexant</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

